skip to Main Content

PI3K protein: Potential new therapeutic target in pancreatic neuroendocrine tumors

Newsfeed image, light gray text on dark gray background
Researchers have demonstrated that selective inactivation of the p110α, PI3K isoform is sufficient to block tumor progression and metastasis in a mice model of PanNETs

Researchers from the ‘Angiogenesis signaling pathways’ research group of the Institute of Biomedical Investigation of Bellvitge (IDIBELL), led by Dr. Mariona Graupera, have unveiled the potential therapeutic benefit of a selective inhibitior of the PI3-kinase (PI3K) protein in pancreatic neuroendocrine tumors (PanNETs). The study, published in the Clinical Cancer Research journal, provides a significant advance in understanding the role of PI3K signaling in cancer and opens new therapeutic opportunities for this and other types of cancer.

Read more . . .

Back To Top